Japan Chemical Research Looks To Grow Market Shares For Growth Hormone Products
This article was originally published in PharmAsia News
Executive Summary
Japan Chemical Research 2008 sales increased by 1.8 percent to ¥12.82 billion, through growth of the company's major product, human growth hormone Growject (somatropin). For fiscal year 2009, the company estimates a 1.8 percent increase in sales and 8 percent increase in income. JCR submitted a new drug application in Japan for recombinant erythropoietin to treat nephrogenic anemia last November, aiming for a market launch in 2010. JCR also begins clinical trials for its mesenchymal stem cell therapeutic agent in Japan. (Click here for more - Japanese language